DK3115372T3 - Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf - Google Patents

Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf Download PDF

Info

Publication number: DK3115372T3
Authority: DK; Denmark
Prior art keywords: enzymfusion; proteins; targeted therapeutic; therapeutic lysosomal; lysosomal
Prior art date: 2012-11-27

Application number

DK16182420.6T

Other languages

English (en)

Inventor

Mika Aoyagi-Scharber

Teresa Margaret Christianson

Melita Dvorak-Ewell

Daniel Wendt

Shinong Long

Jonathan Lebowitz

Daniel Solomon Gold

Original Assignee

Biomarin Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-27

Filing date

2013-11-27

Publication date

2019-06-11

2013-11-27 Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc

2019-06-11 Application granted granted Critical

2019-06-11 Publication of DK3115372T3 publication Critical patent/DK3115372T3/da

Links

230000002132 lysosomal effect Effects 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)

DK16182420.6T 2012-11-27 2013-11-27 Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf DK3115372T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261730378P	2012-11-27	2012-11-27
US201361788968P	2013-03-15	2013-03-15
EP13802834.5A EP2925776B1 (en)	2012-11-27	2013-11-27	Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Publications (1)

Publication Number	Publication Date
DK3115372T3 true DK3115372T3 (da)	2019-06-11

Family

ID=49753532

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK13802834.5T DK2925776T3 (da)	2012-11-27	2013-11-27	Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf
DK16182420.6T DK3115372T3 (da)	2012-11-27	2013-11-27	Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK13802834.5T DK2925776T3 (da)	2012-11-27	2013-11-27	Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf

Country Status (26)

Country	Link
US (9)	US9376480B2 (da)
EP (2)	EP2925776B1 (da)
JP (2)	JP6831176B2 (da)
KR (4)	KR102385392B1 (da)
CN (1)	CN104822701B (da)
AR (1)	AR093626A1 (da)
AU (1)	AU2013352184B2 (da)
BR (1)	BR112015012152B1 (da)
CA (1)	CA2892146A1 (da)
CL (1)	CL2015001371A1 (da)
CY (1)	CY1122555T1 (da)
DK (2)	DK2925776T3 (da)
ES (2)	ES2679374T3 (da)
HR (2)	HRP20181351T1 (da)
HU (2)	HUE039334T2 (da)
IL (3)	IL238824B (da)
LT (1)	LT3115372T (da)
MX (2)	MX377150B (da)
PL (2)	PL3115372T3 (da)
PT (2)	PT2925776T (da)
RS (1)	RS58916B1 (da)
RU (1)	RU2680581C2 (da)
SI (1)	SI3115372T1 (da)
TW (2)	TWI711632B (da)
WO (1)	WO2014085621A1 (da)
ZA (1)	ZA201503509B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20170698T1 (hr) *	2008-05-07	2017-09-22	Biomarin Pharmaceutical Inc.	Lizosomski usmjereni peptidi i njihove uporabe
HUE039334T2 (hu)	2012-11-27	2018-12-28	Biomarin Pharm Inc	Célzott terápiás lizoszómális enzim fúziós fehérjék és azok alkalmazásai
CN105377039A (zh) *	2013-05-15	2016-03-02	明尼苏达大学董事会	腺相关病毒介导的基因向中枢神经系统转移
US10722559B2 (en)	2014-08-11	2020-07-28	Shire Human Genetic Therapies, Inc.	Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
US20180303877A1 (en) *	2014-09-25	2018-10-25	The General Hospital Corporation	Cell-based targeted delivery of pseudonomas exotoxin
WO2016065319A1 (en) *	2014-10-24	2016-04-28	Shire Human Genetic Therapies, Inc.	Lysosomal targeting of enzymes, and uses thereof
TWI752907B (zh) *	2015-05-08	2022-01-21	美商拜奧馬林製藥公司	用於治療cln2疾病之tpp1調配物及方法
MY189159A (en)	2015-07-06	2022-01-29	Regeneron Pharma	Multispecific antigen-binding molecules and uses thereof
AU2016349528A1 (en)	2015-11-06	2018-05-17	Biomarin Pharmaceutical Inc.	Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
EP4275751A3 (en)	2016-02-24	2023-12-27	BioMarin Pharmaceutical Inc.	Improved naglu fusion protein formulation
IL305449B2 (en)	2016-04-15	2026-01-01	Univ Pennsylvania	Gene therapy for the treatment of mucocutaneous type ii diabetes
CL2016003282A1 (es)	2016-12-21	2017-08-18	Univ Chile	Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
FI3635009T3 (fi)	2017-06-07	2026-04-07	Regeneron Pharma	Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
TWI835747B (zh)	2017-09-22	2024-03-21	賓州大學委員會	用於治療黏多醣病 ii 型之基因治療
AU2018345303B2 (en)	2017-10-02	2025-09-18	Denali Therapeutics Inc.	Fusion proteins comprising enzyme replacement therapy enzymes
JP7779653B2 (ja)	2018-02-07	2025-12-03	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	治療用タンパク質送達のための方法および組成物
MA54792A (fr) *	2018-03-09	2021-12-01	Avrobio Inc	Compositions et méthodes pour le traitement de la maladie de parkinson
KR20210005154A (ko) *	2018-04-30	2021-01-13	아미쿠스 세라퓨틱스, 인코포레이티드	유전자 요법 작제물 및 사용 방법
EP3793591A1 (en)	2018-05-17	2021-03-24	Regeneron Pharmaceuticals, Inc.	Anti-cd63 antibodies, conjugates, and uses thereof
EP3802619A1 (en)	2018-06-08	2021-04-14	F. Hoffmann-La Roche AG	Peptidic linker with reduced post-translational modification
AR116624A1 (es)	2018-10-10	2021-05-26	Amicus Therapeutics Inc	Composiciones de polipéptidos estabilizados por enlaces disulfuro y métodos de uso
WO2020102667A2 (en) *	2018-11-16	2020-05-22	Asklepios Biopharmaceutical, Inc.	Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence
CN115087458A (zh) *	2019-10-10	2022-09-20	阿米库斯治疗学公司	变体igf2构建体
JP2023512423A (ja)	2019-12-24	2023-03-27	ジュベナ・セラピューティクス・インコーポレイテッド	再生性ポリペプチドおよびその使用
WO2021183895A1 (en)	2020-03-13	2021-09-16	Biomarin Pharmaceutical Inc.	Treatment of fabry disease with aav gene therapy vectors
KR20240029031A (ko)	2021-06-21	2024-03-05	쥬베나 테라퓨틱스, 인크.	재생 폴리펩티드 및 이의 용도
US20240279360A1 (en)	2021-06-23	2024-08-22	Lycia Therapeutics, Inc.	Bifunctional compounds containing igf-2 polypeptides
CN115975039A (zh) *	2021-10-15	2023-04-18	中山大学	重组融合抗体和抗体-药物偶联物及其用途
EP4654982A1 (en) *	2023-01-27	2025-12-03	Regeneron Pharmaceuticals, Inc.	Modified rhabdovirus glycoproteins and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5206161A (en)	1991-02-01	1993-04-27	Genentech, Inc.	Human plasma carboxypeptidase B
AUPN674895A0 (en)	1995-11-23	1995-12-14	Women's And Children's Hospital	Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
US6217552B1 (en)	1999-03-01	2001-04-17	Coaxia, Inc.	Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
DE10035433C2 (de)	2000-07-20	2002-07-18	Tuma Wolfgang	Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben
US20040005309A1 (en)	2002-05-29	2004-01-08	Symbiontics, Inc.	Targeted therapeutic proteins
ATE384736T1 (de)	2001-04-30	2008-02-15	Zystor Therapeutics Inc	Subzelluläres targeting von therapeutischen proteinen
US7560424B2 (en)	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US7629309B2 (en)	2002-05-29	2009-12-08	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
WO2003032913A2 (en)	2001-10-16	2003-04-24	Symbiontics Inc.	Methods and compositions for targeting proteins across the blood brain barrier
US20030072761A1 (en)	2001-10-16	2003-04-17	Lebowitz Jonathan	Methods and compositions for targeting proteins across the blood brain barrier
US7485314B2 (en)	2002-05-06	2009-02-03	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Induction of antigen specific immunologic tolerance
CA2487815A1 (en)	2002-05-29	2003-12-11	Biomarin Pharmaceutical Inc.	Targeted therapeutic proteins
MXPA05013565A (es)	2003-06-12	2006-03-09	Lilly Co Eli	Proteinas de fusion analogas al glp-1.
US7442372B2 (en)	2003-08-29	2008-10-28	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
CN1922313B (zh) *	2004-02-10	2011-10-26	生物马林医药公司	酸性α-糖苷酶及其片段
CA2600929A1 (en)	2005-03-04	2006-09-14	Biogen Idec Ma Inc.	Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
HRP20170698T1 (hr) *	2008-05-07	2017-09-22	Biomarin Pharmaceutical Inc.	Lizosomski usmjereni peptidi i njihove uporabe
US8697654B2 (en) *	2008-12-18	2014-04-15	E I Du Pont De Nemours And Company	Peptide linkers for effective multivalent peptide binding
US9029530B2 (en)	2009-01-02	2015-05-12	Biomarin Pharmaceutical Inc.	Detection of oligosaccharides
EP2475376B1 (en) *	2009-06-17	2016-03-30	BioMarin Pharmaceutical Inc.	Formulations for lysosomal enzymes
MX362176B (es)	2010-06-25	2019-01-07	Amcor Rigid Plastics Usa Llc	Sistema de depuracion de oxigeno para un recipiente.
CA2805449A1 (en) *	2010-06-25	2011-12-29	Shire Human Genetic Therapies, Inc.	Treatment of sanfilippo syndrome type b
US9409950B2 (en) *	2010-12-23	2016-08-09	Biogen Ma Inc.	Linker peptides and polypeptides comprising same
US8580922B2 (en)	2011-03-04	2013-11-12	Shire Human Genetic Therapies, Inc.	Peptide linkers for polypeptide compositions and methods for using same
BR112013022557A2 (pt) *	2011-03-04	2017-08-01	Shire Human Genetic Therapies	ligantes de peptídeo composições de polipeptídeo e métodos para uso dos mesmos
US9409958B2 (en) *	2011-03-10	2016-08-09	Novozymes, Inc.	Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
HUE039334T2 (hu)	2012-11-27	2018-12-28	Biomarin Pharm Inc	Célzott terápiás lizoszómális enzim fúziós fehérjék és azok alkalmazásai

2013
- 2013-11-27 HU HUE13802834A patent/HUE039334T2/hu unknown
- 2013-11-27 JP JP2015544209A patent/JP6831176B2/ja active Active
- 2013-11-27 KR KR1020217017007A patent/KR102385392B1/ko active Active
- 2013-11-27 MX MX2019009191A patent/MX377150B/es active IP Right Grant
- 2013-11-27 SI SI201331450T patent/SI3115372T1/sl unknown
- 2013-11-27 BR BR112015012152-7A patent/BR112015012152B1/pt active IP Right Grant
- 2013-11-27 HU HUE16182420A patent/HUE043679T2/hu unknown
- 2013-11-27 RU RU2015125491A patent/RU2680581C2/ru active
- 2013-11-27 ES ES13802834.5T patent/ES2679374T3/es active Active
- 2013-11-27 AR ARP130104367A patent/AR093626A1/es active IP Right Grant
- 2013-11-27 AU AU2013352184A patent/AU2013352184B2/en active Active
- 2013-11-27 PL PL16182420T patent/PL3115372T3/pl unknown
- 2013-11-27 HR HRP20181351TT patent/HRP20181351T1/hr unknown
- 2013-11-27 EP EP13802834.5A patent/EP2925776B1/en active Active
- 2013-11-27 CN CN201380061935.4A patent/CN104822701B/zh active Active
- 2013-11-27 CA CA2892146A patent/CA2892146A1/en active Pending
- 2013-11-27 KR KR1020157017224A patent/KR102262882B1/ko active Active
- 2013-11-27 RS RS20190585A patent/RS58916B1/sr unknown
- 2013-11-27 PT PT138028345T patent/PT2925776T/pt unknown
- 2013-11-27 TW TW107114660A patent/TWI711632B/zh active
- 2013-11-27 TW TW102143329A patent/TWI626250B/zh active
- 2013-11-27 KR KR1020227011416A patent/KR102521039B1/ko active Active
- 2013-11-27 MX MX2015006644A patent/MX367024B/es active IP Right Grant
- 2013-11-27 EP EP16182420.6A patent/EP3115372B1/en active Active
- 2013-11-27 PT PT16182420T patent/PT3115372T/pt unknown
- 2013-11-27 US US14/092,336 patent/US9376480B2/en active Active
- 2013-11-27 WO PCT/US2013/072287 patent/WO2014085621A1/en not_active Ceased
- 2013-11-27 KR KR1020237012007A patent/KR20230054482A/ko not_active Ceased
- 2013-11-27 DK DK13802834.5T patent/DK2925776T3/da active
- 2013-11-27 PL PL13802834T patent/PL2925776T3/pl unknown
- 2013-11-27 DK DK16182420.6T patent/DK3115372T3/da active
- 2013-11-27 ES ES16182420T patent/ES2729997T3/es active Active
- 2013-11-27 LT LTEP16182420.6T patent/LT3115372T/lt unknown
2015
- 2015-05-14 IL IL238824A patent/IL238824B/en active IP Right Grant
- 2015-05-19 ZA ZA2015/03509A patent/ZA201503509B/en unknown
- 2015-05-20 CL CL2015001371A patent/CL2015001371A1/es unknown
- 2015-10-14 US US14/883,193 patent/US9834587B2/en active Active
- 2015-10-14 US US14/883,169 patent/US9845346B2/en active Active
- 2015-10-14 US US14/883,203 patent/US9834588B2/en active Active
- 2015-10-14 US US14/883,211 patent/US9771408B2/en active Active
2017
- 2017-08-28 US US15/688,438 patent/US10301369B2/en active Active
2018
- 2018-11-13 IL IL262976A patent/IL262976B/en active IP Right Grant
2019
- 2019-04-08 US US16/378,163 patent/US11254725B2/en active Active
- 2019-05-17 HR HRP20190918TT patent/HRP20190918T1/hr unknown
- 2019-06-06 CY CY20191100600T patent/CY1122555T1/el unknown
- 2019-07-24 JP JP2019136013A patent/JP6913719B2/ja active Active
2020
- 2020-02-23 IL IL272854A patent/IL272854B/en unknown
2022
- 2022-01-10 US US17/572,018 patent/US20220127326A1/en not_active Abandoned
2025
- 2025-01-17 US US19/030,525 patent/US20250388644A1/en active Pending

Also Published As

Publication number	Publication date
WO2014085621A1 (en)	2014-06-05
US9845346B2 (en)	2017-12-19
AR093626A1 (es)	2015-06-17
TW201827468A (zh)	2018-08-01
IL262976B (en)	2020-02-27
ES2729997T3 (es)	2019-11-07
JP2019206556A (ja)	2019-12-05
ZA201503509B (en)	2016-11-30
KR102262882B1 (ko)	2021-06-10
IL262976A (en)	2018-12-31
AU2013352184A1 (en)	2015-06-04
AU2013352184B2 (en)	2018-05-31
CA2892146A1 (en)	2014-06-05
SI3115372T1 (sl)	2019-08-30
EP3115372B1 (en)	2019-03-06
KR20230054482A (ko)	2023-04-24
US10301369B2 (en)	2019-05-28
IL238824B (en)	2018-11-29
US9834587B2 (en)	2017-12-05
US20190225666A1 (en)	2019-07-25
RU2680581C2 (ru)	2019-02-22
MX2019009191A (es)	2019-10-09
US20170355744A1 (en)	2017-12-14
RS58916B1 (sr)	2019-08-30
US20160031963A1 (en)	2016-02-04
JP6831176B2 (ja)	2021-02-17
TW201431884A (zh)	2014-08-16
MX377150B (es)	2025-03-07
CY1122555T1 (el)	2021-01-27
US9376480B2 (en)	2016-06-28
IL238824A0 (en)	2015-06-30
MX2015006644A (es)	2015-08-10
KR20220047892A (ko)	2022-04-19
ES2679374T3 (es)	2018-08-24
HRP20181351T1 (hr)	2018-11-02
IL272854B (en)	2021-07-29
HUE043679T2 (hu)	2019-09-30
US9771408B2 (en)	2017-09-26
KR20150088317A (ko)	2015-07-31
PL3115372T3 (pl)	2019-09-30
JP6913719B2 (ja)	2021-08-04
PT3115372T (pt)	2019-06-12
US11254725B2 (en)	2022-02-22
KR102385392B1 (ko)	2022-04-11
HK1216026A1 (en)	2016-10-07
EP2925776B1 (en)	2018-05-30
RU2015125491A (ru)	2017-01-10
CN104822701B (zh)	2018-09-21
EP2925776A1 (en)	2015-10-07
KR102521039B1 (ko)	2023-04-12
MX367024B (es)	2019-08-02
JP2016505539A (ja)	2016-02-25
DK2925776T3 (da)	2018-09-03
KR20210070389A (ko)	2021-06-14
CN104822701A (zh)	2015-08-05
US20140161788A1 (en)	2014-06-12
US20160039900A1 (en)	2016-02-11
TWI711632B (zh)	2020-12-01
TWI626250B (zh)	2018-06-11
US20160031965A1 (en)	2016-02-04
IL272854A (en)	2020-04-30
HUE039334T2 (hu)	2018-12-28
US20160031964A1 (en)	2016-02-04
US20250388644A1 (en)	2025-12-25
LT3115372T (lt)	2019-06-25
BR112015012152A2 (pt)	2017-08-15
BR112015012152B1 (pt)	2023-04-25
PT2925776T (pt)	2018-07-30
CL2015001371A1 (es)	2015-10-09
US20220127326A1 (en)	2022-04-28
PL2925776T3 (pl)	2018-11-30
HRP20190918T1 (hr)	2019-09-20
US9834588B2 (en)	2017-12-05
EP3115372A1 (en)	2017-01-11

Publication	Publication Date	Title
DK3115372T3 (da)	2019-06-11	Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf
DK3597644T3 (da)	2021-11-08	Kationiske aminlipider og anvendelser deraf
DK3346008T3 (da)	2021-01-11	Rekombinante mikroorganismer og anvendelser deraf
DK2850202T3 (da)	2020-05-18	Fremgangsmåder og grupper
DK2920313T3 (da)	2019-09-02	Rekombinante adenovira og anvendelse deraf
EP2864360A4 (en)	2015-04-29	TARGETED THERAPEUTICS
DK2839860T3 (da)	2019-06-17	Pyrrolobenzodiazepiner og konjugater deraf
DK3470086T3 (da)	2020-12-21	Pyrrolobenzodiazepiner og konjugater deraf
DK2914291T3 (da)	2022-05-16	Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2903600T3 (da)	2022-09-26	Virusholdig formulering og anvendelse deraf
DK3489254T3 (da)	2022-11-07	Målrettede/immunmodulatoriske fusionsproteiner og fremgangsmåder til fremstilling deraf
EP2838909A4 (en)	2016-04-13	TARGETED THERAPEUTICS
DK3608325T3 (da)	2022-08-22	Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
DK2920167T3 (da)	2020-01-20	Hydrazinyl-indol-forbindelser og konjugater
DK2914633T3 (da)	2022-03-14	Antistof/lægemiddel-konjugater og anvendelsesfremgangsmåder
DK3456734T3 (da)	2022-04-19	Serinproteasemolekyler og behandlinger
EP2922416A4 (en)	2016-07-20	MANIPULATED SECRETATED PROTEINS AND METHOD
BR112014009050A2 (pt)	2018-12-04	pirrolbenzodiazepinas e conjugados destas
DK3415157T3 (da)	2020-10-19	N-acyldipeptidderivater og anvendelser deraf
PL2771037T3 (pl)	2017-06-30	Środki terapeutyczne i ich zastosowania
PT2580240T (pt)	2019-03-29	Anticorpos as100a4 e utilizações terapêuticas dos mesmos
BR112015011111A2 (pt)	2017-11-14	proteína multifuncional e formulação farmacêutica
DK2917181T3 (da)	2020-01-13	Heteroarylderivater og anvendelser deraf
DK2782598T3 (da)	2020-08-10	Rekombinante proteiner og terapeutiske anvendelser deraf
DK3173102T3 (da)	2020-02-24	FGFR-FC-fusionsprotein og anvendelse deraf